RESUMO
Purpose: To assess the comparability of ocular biometry measurements and refractive outcomes between ANTERION and IOL Master 700. Methods: This comparative prospective study was conducted from December 2020 to February 2021. A total of 225 patients who had cataracts were enrolled for the study and different parameters such as anterior keratometry (Steep K, Flat K) with axis, Sim K, central corneal thickness (CCT), aqueous depth (AQD), lens thickness (LT), and axial length (AL), white?to?white (WTW) were evaluated in IOL master 700 first and then with ANTERION. Finally, 203 patients completed the 6?week follow?up and the postoperative refraction was done at the 6th week. To assess the agreement between the devices, intraclass coefficient (ICC) and Bland–Altman analysis with 95% limits of agreement (LoA) were used. To analyze the agreement for postoperative residual refractive error between the two devices, Kappa statistics were used. Results: The mean difference for steep K, flat K, and Sim K between ANTERION and IOL Master 700 were ? 0.18 +/?0.26 D, ?0.13+/? 0.28D, ?0.15 +/?0.23, respectively. The CCT, ACD, and LT also showed excellent agreement (ICC > 0.9) but the similarity for the keratometry axis was not up to the mark (ICC = 0.794). For postoperative refractive outcomes, the Kappa value was 0.437, indicating moderate agreement. Conclusion: ANTERION showed a good agreement for the majority of parameters with IOLMaster 700 in measuring ocular biometry, except for the keratometry. The accuracy of the intraocular lens power calculations was clinically acceptable with both biometers though the IOL power given by ANTERION remained slightly on the hypermetropic side.
RESUMO
Purpose: To compare the efficacy of topical nonsteroidal anti?inflammatory drugs (NSAIDs) and prednisolone acetate in controlling inflammation and preventing cystoid macular edema (CME) after uneventful phacoemulsification. Methods: All patients who underwent uneventful phacoemulsification from December 2020 to Feb 2021 were included in the study. These were randomly assigned to receive any one anti?inflammatory agent among topical nepafenac (0.1%) [96 eyes], bromfenac (0.07%) [93 eyes], preservative?free ketorolac (0.4%) [94 eyes], nepafenac (0.3%) [96 eyes], or prednisolone acetate (1%) [91 eyes]. The efficacy of the drugs was evaluated by comparing the grade of anterior chamber (AC) cells, conjunctival hyperemia, pain score, visual acuity, intraocular pressure (IOP), and central macular thickness (CMT) at 1 and 6 weeks after surgery. Results: At 1 and 6 weeks, there was no significant difference in pain score, conjunctival hyperemia, AC cells, change in IOP, and visual acuity between the prednisolone and the NSAIDs groups, though nepafenac 0.3% was most effective. At 6 weeks, there was no significant difference in the number of patients developing subclinical CME in the prednisolone versus NSAID group. The mean increase in CMT was significantly lower in nepafenac 0.3% than prednisolone at 1 and 6 weeks (P = 0.003 and 0.004, respectively). Conclusion: NSAIDs used in isolation are comparable to prednisolone in preventing inflammation and pain after uneventful phacoemulsification. However, nepafenac 0.3% is most comparable to prednisolone and more efficacious in reducing the incidence of CME. We recommend that nepafenac 0.3% can be used as a sole anti?inflammatory agent in patients with uneventful phacoemulsification.